Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone for Relapsed/Refractory Myeloma
NCT01332617Phase 2Withdrawn
- Sponsor
- University of Louisville
- Start
- Apr 2011
- Primary completion
- Feb 2018
- Modality
- Modified Peptides, Orthosteric Ligands
01
Overview
A Phase 2 trial of simvastatin, zoledronic acid, bortezomib, bendamustine, methylprednisolone injection in multiple myeloma (MM), sponsored by University of Louisville. Planned start Apr 2011; status: withdrawn.
02
Drugs
simvastatinzoledronic acidbortezomibbendamustinemethylprednisolone injection
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01332617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332617.